HK1162916A1 - Methods of treatment for solid tumors - Google Patents

Methods of treatment for solid tumors

Info

Publication number
HK1162916A1
HK1162916A1 HK12102489.0A HK12102489A HK1162916A1 HK 1162916 A1 HK1162916 A1 HK 1162916A1 HK 12102489 A HK12102489 A HK 12102489A HK 1162916 A1 HK1162916 A1 HK 1162916A1
Authority
HK
Hong Kong
Prior art keywords
treatment
methods
solid tumors
tumors
solid
Prior art date
Application number
HK12102489.0A
Other languages
English (en)
Chinese (zh)
Inventor
Kamal D Puri
Jerry B Evarts
Brian Lannutti
Neill A Giese
Original Assignee
Gilead Calistoga Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42247670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1162916(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Calistoga Llc filed Critical Gilead Calistoga Llc
Publication of HK1162916A1 publication Critical patent/HK1162916A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102489.0A 2009-04-20 2012-03-12 Methods of treatment for solid tumors HK1162916A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17104709P 2009-04-20 2009-04-20
PCT/US2010/031794 WO2010123931A1 (fr) 2009-04-20 2010-04-20 Procédés de traitement de tumeurs solides

Publications (1)

Publication Number Publication Date
HK1162916A1 true HK1162916A1 (en) 2012-09-07

Family

ID=42247670

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102489.0A HK1162916A1 (en) 2009-04-20 2012-03-12 Methods of treatment for solid tumors

Country Status (18)

Country Link
US (2) US8546409B2 (fr)
EP (1) EP2421536B1 (fr)
JP (1) JP2012524126A (fr)
KR (1) KR20120005523A (fr)
CN (1) CN102458410A (fr)
AP (1) AP2011005956A0 (fr)
AU (1) AU2010239312A1 (fr)
CA (1) CA2759724A1 (fr)
CL (1) CL2011002622A1 (fr)
CR (1) CR20110560A (fr)
EA (1) EA201101507A1 (fr)
ES (1) ES2548253T3 (fr)
HK (1) HK1162916A1 (fr)
IL (2) IL215767A0 (fr)
MX (1) MX2011011036A (fr)
PT (1) PT2421536E (fr)
SG (1) SG175259A1 (fr)
WO (1) WO2010123931A1 (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE202004021949U1 (de) 2003-09-12 2013-05-27 Vessix Vascular, Inc. Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
WO2008049082A2 (fr) 2006-10-18 2008-04-24 Minnow Medical, Inc. Induction d'effets souhaitables de température sur un tissu humain
EP2076194B1 (fr) 2006-10-18 2013-04-24 Vessix Vascular, Inc. Système pour induire des effets thermiques désirables sur un tissu anatomique
JP5312337B2 (ja) 2006-10-18 2013-10-09 べシックス・バスキュラー・インコーポレイテッド 標的組織の選択的な処置のための調節されたｒｆエネルギーおよび電気的な組織の特徴付け
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA3092449A1 (fr) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies pour tumeurs malignes hematologiques
CN102271603A (zh) 2008-11-17 2011-12-07 明诺医学股份有限公司 得知或未得知组织形态的选择性能量积累
EP2411391A1 (fr) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
JP2013523318A (ja) 2010-04-09 2013-06-17 べシックス・バスキュラー・インコーポレイテッド 組織の治療のための発電および制御の装置
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012100095A1 (fr) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Cathéter à grande électrode compatible avec un guide pour ablation de nerf rénal à lésion artérielle réduite
AP2013007158A0 (en) * 2011-03-11 2013-10-31 Gilead Calistoga Llc Combination therapies for hematologic malignancies
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
CN102885854B (zh) * 2011-07-22 2014-09-10 彦臣生技药品股份有限公司 台湾绿蜂胶萃取物用于减缓患者病情发展的用途
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
WO2013055826A1 (fr) 2011-10-10 2013-04-18 Boston Scientific Scimed, Inc. Dispositifs médicaux comprenant des électrodes d'ablation
EP2765940B1 (fr) 2011-10-11 2015-08-26 Boston Scientific Scimed, Inc. Dispositif d'électrode hors paroi pour une modulation nerveuse
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
EP3366250A1 (fr) 2011-11-08 2018-08-29 Boston Scientific Scimed, Inc. Ablation ostiale du nerf rénal
EP2779929A1 (fr) 2011-11-15 2014-09-24 Boston Scientific Scimed, Inc. Dispositif et procédés pour surveiller la modulation nerveuse rénale
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
EP2790705B1 (fr) 2011-12-15 2017-12-06 Novartis AG Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9037259B2 (en) 2011-12-23 2015-05-19 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013169927A1 (fr) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Dispositifs de modulation du nerf rénal
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
DK3260455T3 (da) 2012-07-04 2019-06-11 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
CN104540465A (zh) 2012-08-24 2015-04-22 波士顿科学西美德公司 带有含单独微孔隙区域的球囊的血管内导管
EP2895095A2 (fr) 2012-09-17 2015-07-22 Boston Scientific Scimed, Inc. Système et procédé d'électrode à positionnement automatique pour une modulation de nerf rénal
WO2014047411A1 (fr) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Système de modulation des nerfs et blocage des nerfs par gradient thermique inoffensif
WO2014047454A2 (fr) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Cathéter d'ablation par ultrasons à refroidissement automatique
JP6074051B2 (ja) 2012-10-10 2017-02-01 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 血管内神経変調システム及び医療用デバイス
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
WO2014128612A1 (fr) * 2013-02-20 2014-08-28 Novartis Ag Dérivés de quinazolin-4-one
WO2014143571A1 (fr) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Dispositifs médicaux pour moduler des nerfs
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
EP2967725B1 (fr) 2013-03-15 2019-12-11 Boston Scientific Scimed, Inc. Unité de commande de détection de fuite électrique entre des plots d'électrodes et système comprenant une telle unité de commande
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
EP2967734B1 (fr) 2013-03-15 2019-05-15 Boston Scientific Scimed, Inc. Procédés et appareils pour remodéliser un tissu de ou adjacent à un passage corporel
CN105473092B (zh) 2013-06-21 2019-05-17 波士顿科学国际有限公司 具有可旋转轴的用于肾神经消融的医疗器械
EP3010437A1 (fr) 2013-06-21 2016-04-27 Boston Scientific Scimed, Inc. Cathéter à ballonnet pour énervation rénale à support d'électrode accompagnant
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
WO2015002787A1 (fr) 2013-07-01 2015-01-08 Boston Scientific Scimed, Inc. Dispositifs médicaux pour une ablation de nerf rénal
EP3019105B1 (fr) 2013-07-11 2017-09-13 Boston Scientific Scimed, Inc. Dispositifs de modulation nerveuse
EP3019106A1 (fr) 2013-07-11 2016-05-18 Boston Scientific Scimed, Inc. Dispositif médical équipé d'ensembles électrodes extensibles
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
JP6122217B2 (ja) 2013-07-22 2017-04-26 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 腎神経アブレーション用医療器具
WO2015013205A1 (fr) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Dispositifs médicaux pour l'ablation de nerfs rénaux
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
EP3035879A1 (fr) 2013-08-22 2016-06-29 Boston Scientific Scimed, Inc. Circuit flexible ayant une adhérence améliorée à un ballon de modulation de nerf rénal
EP3041425B1 (fr) 2013-09-04 2022-04-13 Boston Scientific Scimed, Inc. Cathéter à ballonnet à radiofréquences (rf) ayant une capacité de rinçage et de refroidissement
WO2015038947A1 (fr) 2013-09-13 2015-03-19 Boston Scientific Scimed, Inc. Ballonnet d'ablation à couche de revêtement déposée en phase vapeur
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
AU2014334574B2 (en) 2013-10-15 2017-07-06 Boston Scientific Scimed, Inc. Medical device balloon
JP6259099B2 (ja) 2013-10-18 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 可撓性を備える導電性ワイヤを備えるバルーン・カテーテル、並びに関連する使用および製造方法
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
EP3083623A1 (fr) 2013-12-20 2016-10-26 Gilead Calistoga LLC Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
CA2934531C (fr) 2013-12-20 2020-02-25 Gilead Calistoga Llc Procedes de synthese d'inhibiteurs de la phosphatidylinositol 3-kinase
EP3091922B1 (fr) 2014-01-06 2018-10-17 Boston Scientific Scimed, Inc. Ensemble circuit souple résistant aux déchirures
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
WO2015119890A1 (fr) 2014-02-04 2015-08-13 Boston Scientific Scimed, Inc. Variante de placement de capteurs thermiques sur une électrode bipolaire
WO2015179772A1 (fr) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Composés phénylquinazolinone et phénylisoquinolinone deutérés
PT3149000T (pt) 2014-05-27 2021-07-27 Rhizen Pharmaceuticals S A Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
SG11201610770PA (en) 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
EP3209664B1 (fr) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Composés aminés hétéroaryliques bicycliques utilisés comme inhibiteurs de pi3k
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2017000125A1 (fr) 2015-06-29 2017-01-05 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
CN106727633A (zh) * 2016-12-20 2017-05-31 井冈山市红扁担科技有限公司 一种具有治疗肺腺癌作用的组合物及其应用
CN110354130B (zh) * 2018-04-09 2024-08-13 上海威道生物医药有限公司 喹唑啉类化合物在治疗具有EGFRv3活化突变的癌症药物中的用途
WO2019196621A1 (fr) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 Utilisation d'un composé de quinazoline dans un médicament pour le traitement de cancers avec mutation d'activation d'egfrv3
WO2019196620A1 (fr) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 Utilisation d'un composé de quinazoline et d'avastin dans la préparation d'un médicament de prévention de maladie combiné
CN110354261B (zh) * 2018-04-09 2023-01-24 威尚（上海）生物医药有限公司 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (fr) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
NL7204972A (fr) 1971-04-21 1972-10-24
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
EP0771204A4 (fr) 1994-08-12 1999-10-20 Pro Neuron Inc Procedes permettant de traiter la sepsie ou des maladies inflammatoires avec des nucleosides a base d'oxypurine
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
EP0904107B1 (fr) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
KR100375155B1 (ko) 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
WO1997041097A2 (fr) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ATE303997T1 (de) 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
AU8280798A (en) 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
BR0312752A (pt) 2002-07-10 2005-04-26 Applied Research Systems Derivados de benzeno fundido de azolidinona-vinil
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (fr) 2002-09-19 2004-03-19 University Health Network Compositions et methodes pour traiter une maladie du coeur
SI1549652T1 (sl) 2002-09-30 2009-04-30 Bayer Healthcare Ag Kondenzirani azolpirimidinski derivati
BR0316386A (pt) 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
EP1581529A1 (fr) 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines et leurs derives en tant qu'inhibiteurs de pi3ks
NZ542475A (en) 2003-04-03 2009-04-30 Semafore Pharmaceuticals Inc PI-3 kinase inhibitor prodrugs
MXPA05012953A (es) 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
WO2004108708A1 (fr) 2003-06-05 2004-12-16 Warner-Lambert Company Llc Indoles 3-substitues et leurs derives utilises comme agents therapeutiques
BRPI0410913A (pt) 2003-06-05 2006-06-27 Warner Lambert Co benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
DE602004007268D1 (de) 2003-06-05 2007-08-09 Warner Lambert Co CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
EP1644364A1 (fr) 2003-06-05 2006-04-12 Warner-Lambert Company LLC Benzofurancarboxamides de tetrazole actifs par rapport aux p13k, utiles comme agents therapeutiques
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
WO2005016348A1 (fr) 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005067901A2 (fr) 2004-01-08 2005-07-28 Michigan State University Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension
HUE030950T2 (en) * 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CA2566436C (fr) * 2004-05-13 2011-05-10 Vanderbilt University Inhibiteurs selectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenese
CA2567883A1 (fr) 2004-05-25 2005-12-15 Icos Corporation Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
WO2006089106A2 (fr) * 2005-02-17 2006-08-24 Icos Corporation Procede d'inhibition d'accumulation de leucocytes
EP2120909A2 (fr) * 2006-12-15 2009-11-25 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
US20090131512A1 (en) 2007-10-31 2009-05-21 Dynavax Technologies Corp. Inhibition of type I in IFN production
CA3092449A1 (fr) * 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies pour tumeurs malignes hematologiques
WO2010065923A2 (fr) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Médicaments à ciblage phosphatidylinositol-3-kinase p110 delta dans le traitement des troubles du snc
JP5719779B2 (ja) 2008-12-24 2015-05-20 プラナ バイオテクノロジー リミティッド キナゾリノン化合物
EP2411391A1 (fr) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
JP2013504604A (ja) 2009-09-18 2013-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体

Also Published As

Publication number Publication date
SG175259A1 (en) 2011-11-28
US20130344138A1 (en) 2013-12-26
IL215767A0 (en) 2012-01-31
ES2548253T3 (es) 2015-10-15
MX2011011036A (es) 2012-01-20
EA201101507A1 (ru) 2012-05-30
EP2421536A1 (fr) 2012-02-29
AP2011005956A0 (en) 2011-10-31
CL2011002622A1 (es) 2012-07-20
CA2759724A1 (fr) 2010-10-28
AU2010239312A1 (en) 2011-11-10
US8546409B2 (en) 2013-10-01
KR20120005523A (ko) 2012-01-16
CR20110560A (es) 2012-02-02
CN102458410A (zh) 2012-05-16
PT2421536E (pt) 2015-10-20
WO2010123931A1 (fr) 2010-10-28
IL234624A0 (en) 2014-11-30
US20110044942A1 (en) 2011-02-24
JP2012524126A (ja) 2012-10-11
EP2421536B1 (fr) 2015-08-26

Similar Documents

Publication Publication Date Title
HK1162916A1 (en) Methods of treatment for solid tumors
IL218575A0 (en) Treatment of cancer
IL229878A0 (en) Compounds for the treatment of cancer
EP2542081A4 (fr) Composés destinés au traitement du cancer
HK1169804A1 (zh) 治療疼痛的方法
EP2558109A4 (fr) Méthode de traitement de tumeurs solides
HK1217763A1 (zh) 用於治療疾病的方法
IL208354A0 (en) Methods of treatment
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
EP2608671A4 (fr) Composés utilisés dans le traitement du cancer
EP2544686A4 (fr) Procédés combinés pour le traitement de maladies
EP2477635A4 (fr) Méthodes de traitement de tumeurs cérébrales
IL218230A0 (en) Method of treating cancer
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
EP2214485A4 (fr) Méthodes de traitement du cancer
EP2440238A4 (fr) Méthodes de traitement
GB201019034D0 (en) Treatment for tumors
GB0913427D0 (en) Compounds for treatment of imflammation
GB0921757D0 (en) Treatment of cancer
GB0817056D0 (en) Polypeptide for treatment of cancer
GB0921823D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200418